1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global T-Cell Lymphoma Treatment Market
2.3. Global T-Cell Lymphoma Treatment Market, By Type, 2025 (US$ Million)
2.4. Global T-Cell Lymphoma Treatment Market, By Drugs, 2025 (US$ Million)
2.5. Global T-Cell Lymphoma Treatment Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025

3. T-Cell Lymphoma Treatment Market: Competitive Analysis
3.1. Market Positioning of Key T-Cell Lymphoma Treatment Market Vendors
3.2. Strategies Adopted by T-Cell Lymphoma Treatment Market Vendors

4. T-Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global T-Cell Lymphoma Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Peripheral T-Cell Lymphoma
5.3.2. Anaplastic Large Cell Lymphoma
5.3.3. Angioimmunoblastic T-Cell Lymphoma
5.3.4. Cutaneous T-Cell Lymphoma
5.3.5. Adult T-Cell Leukemia/Lymphoma
5.3.6. Others (Lymphoblastic lymphoma, Enteropathy-associated intestinal T-cell lymphoma, and Extranodal T-cell lymphoma)

6. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Chemotherapy Drugs
6.3.1.1. Cyclophosphamide
6.3.1.2. Doxorubicin
6.3.1.3. Vincristine
6.3.1.4. Etoposide
6.3.1.5. Gemcitabine
6.3.1.6. Pralatrexate
6.3.1.7. Navelbine
6.3.1.8. Others (Oxaliplatin, Gemcitabine, Cholormethine, Methotrexate & Mechlorethamine)
6.3.2. Corticosteroids
6.3.2.1. Prednisone
6.3.2.2. Dexamethasone
6.3.3. Immunomodulators
6.3.3.1. Lenalodimide
6.3.3.2. Interferon alfa-2b
6.3.3.3. Cyclosporine
6.3.3.4. Imiquimod
6.3.3.5. Bexarotene
6.3.3.6. Tazarotene
6.3.3.7. Forodesine (Mundesine)
6.3.4. Targeted Therapy Drugs
6.3.4.1. Alemtuzumab
6.3.4.2. Belinostat
6.3.4.3. Brentuximab vedotin
6.3.4.4. Romidespin
6.3.4.5. Rituximab
6.3.4.6. Mogamulizumab
6.3.4.7. Nivolumab
6.3.5. Gene Therapy Drugs
6.3.5.1. Yescarta (axicabtagene ciloleucel)
6.3.5.2. Kymirah (tisagenlecleucel)

7. North America T-Cell Lymphoma Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
7.3. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
7.4. T-Cell Lymphoma Treatment Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
7.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
7.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
7.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)

8. UK and European Union T-Cell Lymphoma Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.3. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4. T-Cell Lymphoma Treatment Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.4.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.5.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
8.4.1.6.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)

9. Asia Pacific T-Cell Lymphoma Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.3. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4. T-Cell Lymphoma Treatment Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.4.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.5.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
9.4.1.6.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)

10. Latin America T-Cell Lymphoma Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
10.3. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
10.4. T-Cell Lymphoma Treatment Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
10.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
10.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
10.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)

11. Middle East and Africa T-Cell Lymphoma Treatment Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
11.3. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
11.4. T-Cell Lymphoma Treatment Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
11.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
11.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2024-2034, USD (Million)
11.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2024-2034, USD (Million)

12. Company Profile
12.1. Actelion Pharmaceuticals (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Spectrum Pharmaceuticals
12.3. Bristol-Myers Squibb
12.4. Shenzen ChipScreen Biosciences, Ltd.
12.5. Celgene Corporation
12.6. Eisai, Inc.
12.7. Genmab A/S
12.8. Galderma S.A.
12.9. Kyowa Hakko Kirin Co., Ltd.
12.10. Novartis AG
12.11. Neumedicines, Inc.
12.12. Amgen, Inc.
12.13. F. Hoffman La-Roche
12.14. Seattle Genetics
12.15. Soligenix, Inc.
12.16. ZIOPHARM Oncology
12.17. Medivir AB
12.18. Kura Oncology, Inc.
12.19. Aleron Therapeutics
12.20. Autolus Therapeutics plc
12.21. Innate Pharma
12.22. miRagen Therapeutics, Inc.
12.23. Trillium Therapeutics Inc.
12.24. Bellicum Pharmaceuticals, Inc.
12.25. Sorrento Therapeutics, Inc.